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injection cost of $23.10, and office visit cost of $42.45. RESULTS: The annual 
average drug costs per patient were $4,590 (DA) and $5,244 (EA). Average drug 
costs for administrations were $92 (DA) and $277 (EA). Per member per year 
(PMPY) costs were $4,682 (DA) and $5,521(EA). The annual total costs per 
population (n=1,755) were $8,217,612 (DA) and $9,688,952 (EA). CONCLUSIONS: 
DA Q3W has the potential to provide cost savings over EA QW in terms of annual 
average drug cost per patient ($654 savings), per member per year ($839 savings), 
and total cost per population ($1,471,340 savings). DA Q3W may offer a cost 
advantage over EA QW as it allows for synchronizing of anemia management 
with ongoing cancer treatments, which may reduce required patient visits and 
blood tests.  
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OBJECTIVES: The purpose of this study was to evaluate financial impact on 
Russian National Healthcare Service (RNHS) budget of the introduction of 
Cabazitaxel in second-line treatment of patients with mHRPC previously treated 
with a Docetaxel-containing regimen in first-line. METHODS: The numbers of 
mHRPC patients eligible for first-line and second-line treatment were estimated 
based on local demographic figures, incidence data and experts opinion. A BIA 
model combined the data of official algorithms (standard of treatment approved 
by Ministry of Health of Russian Federation) and guidelines of mPC management, 
as well as local expert opinion and published data on resource use and unit costs 
from published sources. The BIA model stimulates the impact of mHRPC second-
line management with or without Cabazitaxel. Resources to manage first-line 
and second-line treatment included standard chemotherapy, premedication,  
G-CSF prophylaxis, concomitant medications, management of adverse events, 
visits and diagnostics. RESULTS: It was estimated that in the first three years 
following Cabazitaxel introduction in second-line mHRPC patients treatment 
regimen, just 104, 259 and 311 out of 1036 eligible patients with mHRPC 
previously treated with a Docetaxel-containing regimen in first-line would be 
placed on Cabazitaxel therapy respectively. It would imply moderate 
incremental cost of 121.8, 304.6 and 365.5 mln RUB for second-line treatment of 
mHRPC respectively. From the other hand cost for first-line treatment would 
significantly decline due generic erosion of Docetaxel, resulting in following cost 
savings 248.8, 289.0 and 325.2 mln RUB, respectively. As the result the total 
incremental budget increase will be 15,6 and 40,3 mln RUB on second and third 
years of Cabazitaxel introduction, respectively. CONCLUSIONS: Because of small 
size of estimated candidate population the incremental financial budget impact 
on RHNS following the introduction of Cabazitaxel would be very small and 
offset by savings from first-line treatment due to generic erosion of Docetaxel 
price.  
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OBJECTIVES: Melanoma accounts for less than 5% of skin cancers, but is 
responsible for 90% of skin cancer-related deaths worldwide. According to 
Brazilian Institute of Cancer 2012 statistics, it was estimated 6,230 cases of 
melanoma. BRAF mutations occur in approximately 50% of cases, being 
associated with poorer patient prognosis in advanced melanoma. Historically, 
there have been limited treatment options for advanced melanoma, resulting in 
a critical unmet clinical need for more effective therapies. Vemurafenib is a 
novel targeted therapy, effective for BRAF-V600 mutation-positive unresectable 
or metastatic melanoma treatment, orally administrated and available in 
Brazilian market since 2012. Therefore, the aim of this study was estimate the 
economic impact of vemurafenib reimbursement in Brazilian Private Healthcare 
System Budget. METHODS: Based on an epidemiologic approach, the potential 
number of patients for vemurafenib was estimated. Only the private market was 
considered, accounting for 40% of all patients and only drug costs were 
evaluated. The ex-factory price and labeled dose of 960mg b.i.d. were used. 
Average therapy duration of 6 months was assumed. Costs were reported in 
Brazilian Reais (BRL1.00~USD0.48 Dec. 2012). A total health assistance budget of 
BRL67.9 billion was considered, according to Brazilian National Agency for 
Supplementary Health data from 2012. RESULTS: A total of 756 cases of 
advanced melanoma are expected in 2013 in the private system, corresponding 
potentially to 378 patients harboring BRAF-V600E mutation. Treating all potential 
patients with vemurafenib would yield a total drug cost of BRL59.101.395, 
corresponding to a potential budget impact of 0.087%, considering health 
assistance budget. Cost savings owing to oral administration was not considered. 
CONCLUSIONS: By identifying the patients with BRAF-V600E mutation, therapy 
can be targeted to those who present a higher chance to respond to treatment, 
resulting in a potential low impact of vemurafenib in private health care system 
budget, mainly because of its very selected and specific eligible population.  
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OBJECTIVES: To identify the dominant scheme of adjuvant breast cancer therapy 
(comparing the two chemotherapy regimens - 6FAÑ (6 cycles: 5-Fluorouracil + 
Doxorubicin + Cyclophosphamide) vs 6DAC (6 cycles: Docetaxel + Doxorubicin + 
Cyclophosphamide)). METHODS: Based on the Markov model, the cost of 
treatment for breast cancer was evaluated; an â òî æå âgåìÿ analysis of direct 
and indirect costs was conducted. Direct costs included cost of adjuvant 
chemotherapy (6FAC and 6DAC), medical services, adjuvant endocrine therapy, 
cardiac monitoring, current therapy cost and cost of treatment complications. 
Indirect costs included cost of patient’s disability, maintenance of orphans, GDP 
losses caused by mortality and disability and sick-pay. RESULTS: Based on a 
clinical study BCIRG 001 (Martin M, Mackey J, Pienkowski T) and as an outcome 
of Markov simulation it was determined that the use of 6DAC for adjuvant 
therapy in 10 year horizon of research allows to increase the disease-free 
survival by 6.09%, and overall survival by 5,88% comparing to 6FAC. Use of 6DAC 
instead of 6FAC allows to reduce the number of patients with local relapse, 
regional relapse and metastasis insignificantly as well. In the result of direct 
costs analysis it was determined that for 10-years horizon cost rate for the 
treatment of one patient with breast cancer will be $66,026 for 6DAC and $60,845 
for 6FAC. Direct and indirect costs rate of the breast cancer treatment were 
$84,818 and $85,991 for the 6DAC and 6FAC schemes respectively. 
CONCLUSIONS: It was determined that the scheme of adjuvant therapy that 
includes Docetaxel besides of addition efficiency, allows to reduce the cost rate 
to $1173 in 10 years.  
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OBJECTIVES: Lung cancer (LC) is one of the major health problems due its high 
mortality. The most common type of LC is non-small cell lung cancer (NSCLC), 
which accounts for approximately 80% of all LC cases; approximately 3%-5% of 
these have a gene defect called ALK (anaplastic lymphoma kinase). The aim of 
this study was to evaluate the budgetary impact of adding crizotinib for patients 
with ALK-positive advanced NSCLC in Colombia. METHODS: A budget-impact 
model was developed to evaluate crizotinib from the payer perspective. 
Comparators were: crizotinib (250mg bid), erlotinib (150mg/day), 
bevacizumab/platinum doublet (15mg/kg/Carboplatin AUC6+Paclitaxel 200mg/m2 
per cycle [28 days]), paclitaxel/platinum (Carboplatin AUC6+Paclitaxel 200mg/m2 
per cycle), docetaxel/platinum (Cisplatin 75mg/m2 + Docetaxel 75mg/m2 per 
cycle), pemetrexed/platinum (Carboplatin AUC6+Pemetrexed 500mg/m2 per 
cycle), gemcitabine/platinum (Cisplatin 75mg/m2 day1+Gemcitabine 
2,500mg/m2per cycle). Two scenarios were compared: (1) no tested patients, 
excluding crizotinib (2) all patients tested with FISH (diagnostic test) to identify 
ALK-positive NSCLC patients; it was taken into account a positive match for ALK 
of 4.2% and only 3% receiving crizotinib. Epidemiology and acquisition, 
administration and adverse events costs were estimated from Colombian 
sources, values are expressed in 2012 US$. RESULTS: Considering Colombian 
population >18 years (incident rate of LC 0.018%, proportion NSCLC 87.86% and 
advanced NSCLC 52.29%), it was estimated a cohort of 4768 advanced NSCLC 
patients, overall 1-year costs of treating patients with NSCLC would be 
US$197,929,584 with crizotinib, compared with US$190,725,844 without 
crizotinib. Acquisition costs of crizotinib were offset by reductions in adverse 
events (AE) costs (anemia, anorexia, asthenia, diarrhea, dyspnea, fatigue, 
neutropenia, neutropenic infection, nausea, vomiting, pulmonary events,). 
Administration costs accounted between 37.77%-38.16% of total costs, while AE 
management costs made up 1.19% to 1.27% of total costs. CONCLUSIONS: 
Treating ALK-positive advanced NSCLC patients with crizotinib, leads to a 
decrease in total costs of managing adverse events (US$65,042) and progression 
costs.  
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OBJECTIVES: Develop budget impact model to forecast total cost of treatment for 
cutaneous T-cell lymphoma (CTCL) for U.S. public and private payer. METHODS: 
The clinical efficacy and safety data were obtained from the published pivotal 
study results. Costs of adverse events were estimated based on claims database 
analysis, AHRQ’s HCUP, and CMS Medicare 2009 databases. Drug cost was 
estimated based on 2011 AWP price. Epidemiology data was obtained from NCI-
SEER and CDC databases. A budget impact model was implemented over a period 
of five years, based on a stable population and on different penetration and 
substitution rates of newly approved therapy. Model was developed in excel 
based format. Blinded Model design and outputs were tested with payers and 
KOLs. RESULTS: For rare cancers such as CTCL, the budget impact of treatment 
with targeted cancer therapies is in the range of $460,000-$530,000 per 1 million 
covered lives. The per patient per member (PPPM) budget impact of this 
treatment is 46-53 cents. U.S. payers rated PPPM output as the one of the most 
important relevant outputs of model. CONCLUSIONS: This budget impact model 
shows that new treatments for rare forms of cancer are likely to have minimal 
budget impact on payers. PPPM based outputs are more relevant to payers, than 
per patient treatment costs. However, an emerging concern is the total budget 
